share_log

Morgan Stanley Initiates Coverage On Dyne Therapeutics With Overweight Rating, Announces Price Target of $40

Morgan Stanley Initiates Coverage On Dyne Therapeutics With Overweight Rating, Announces Price Target of $40

摩根士丹利以增持评级启动对达因疗法的报道,宣布目标股价为40美元
Benzinga ·  04/30 05:17

Morgan Stanley analyst Michael Ulz initiates coverage on Dyne Therapeutics (NASDAQ:DYN) with a Overweight rating and announces Price Target of $40.

摩根士丹利分析师迈克尔·乌尔兹以增持评级启动了对达因疗法(纳斯达克股票代码:DYN)的报道,并宣布目标股价为40美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发